Search results for "interleukin-6"

showing 10 items of 370 documents

Dendritic Cells Lose Ability to Present Protein Antigen after Stimulating Antigen-Specific T Cell Responses, despite Upregulation of MHC Class II Exp…

2000

Abstract Immature dendritic cells (DC) take up, process and present protein antigens; mature DC are specialized for stimulating primary T cell responses with increased expression of MHC class II and co-stimulatory molecules, but are incapable of processing and presenting soluble protein. The current study examined whether maturation of DC is triggered by T cell recognition of antigens presented by immature DC. Human DC derived from CD34+ progenitor cells by culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) in serum-free medium could prime naive CD4+ T cells to keyhole limpet hemocyanin (KLH) and ovalbumin (OVA). The cultured DC retained the abil…

CD4-Positive T-LymphocytesTime FactorsOvalbuminT cellImmunologyCD1Bone Marrow CellsCell CommunicationCulture Media Serum-FreeInterferon-gammaInterleukin 21medicineHumansImmunology and AllergyCytotoxic T cellIL-2 receptorCD40 AntigensAntigen-presenting cellCells CulturedAntigen PresentationMHC class IIbiologyInterleukin-6Tumor Necrosis Factor-alphaHistocompatibility Antigens Class IIGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationDendritic CellsHematologyIntercellular Adhesion Molecule-1Natural killer T cellMolecular biologyCoculture Techniquesmedicine.anatomical_structureHemocyaninsB7-1 Antigenbiology.proteinImmunobiology
researchProduct

Activin-A, myostatin and interleukin-6 in cancer associated cachexia

2017

Cachexia is a muscle wasting condition associated with multiple different chronic illnesses, such as cancer, diabetes and AIDS. In cancer, approximately 80% of patients with advanced disease have symptoms of muscle wasting, and around 25% of cancer mortality concerns cachexia. Elevated serum levels of different cytokines and TGF-β protein family members, such as Interleukin-6, Myostatin and Activin-A, have been observed in cachetic patients and test animals. However, the mechanistic role and the relative contribution of these molecules to muscle loss in the syndrome have not yet been fully elucidated. In this thesis, the gene-expression levels of Activin-A, Myostatin and Interleukin-6 was a…

CachexiamyostatiiniInterleukin-6interleukiinitaktiviini-aActivin-AsyöpätauditkakeksiaC2C12proteiinitMyostatinmusculoskeletal systemhormones hormone substitutes and hormone antagonists
researchProduct

Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effe…

2001

We investigated the antitumour effects of interleukin 6 (IL-6) on hepatocarcinoma HepG2 cells, endowed with high levels of a mutated, non-degradable, beta-catenin. IL-6 produced minimal growth-inhibitory effects and no apoptosis or gross changes in cell adhesion. Interestingly, however, it caused a consistent decrease in the cytoplasmic levels of wild-type, but not of mutated, beta-catenin protein. There was no effect on E-cadherin or gamma-catenin and a reduction in alpha-catenin occurred only at high concentrations. IL-4, a non-related cytokine, did not modify the content of beta-catenin. IL-6 did not influence beta-catenin mRNA levels. LiCl, a potent inhibitor of Glycogen Synthase Kinase…

Cancer ResearchCarcinoma Hepatocellularmedicine.medical_treatmentBlotting WesternDown-RegulationApoptosisEnzyme-Linked Immunosorbent AssayBiologyDownregulation and upregulationGSK-3Tumor Cells CulturedmedicineHumansRNA MessengerInterleukin 6beta CateninInterleukin 4Interleukin-6Cell growthLiver NeoplasmsWild typeCell biologyCytoskeletal ProteinsCytokineOncologyCateninTrans-ActivatorsCancer researchbiology.proteinEuropean Journal of Cancer
researchProduct

Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro.

2001

Abstract Objective We recently established transgenic animals expressing either interleukin-6 (IL-6) or the soluble IL-6 receptor (sIL-6R) alone, or both components, IL-6 and the sIL-6R, in the liver. This animal model demonstrated that the expression of IL-6 in combination with its sIL-6R led to extramedullary expansion of hematopoietic progenitor cells in the spleen and liver. Materials and Methods We studied other relevant hematopoietic cytokines involved in the IL-6/sIL-6R–induced stimulation of hematopoiesis. Results Using immunohistochemistry, we showed that cell-associated stem cell factor (SCF) and Flt-3L expression were upregulated in liver and spleen only in double transgenic mice…

Cancer ResearchStromal cellCD34Fluorescent Antibody TechniqueStem cell factorMice TransgenicMiceDownregulation and upregulationIn vivoGeneticsAnimalsHumansRNA MessengerReceptorInterleukin 6Molecular BiologyImmunosorbent TechniquesStem Cell FactorbiologyInterleukin-6Membrane ProteinsCell BiologyHematology3T3 CellsFibroblastsBlotting NorthernHematopoietic Stem CellsMolecular biologyImmunohistochemistryReceptors Interleukin-6HaematopoiesisGene Expression RegulationLiverSolubilityHematopoiesis Extramedullarybiology.proteinSpleenExperimental hematology
researchProduct

Transforming growth factor-β1, β2, and β3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones

1993

8701-BC is a recently characterized cell line isolated from a primary ductal infiltrating carcinoma of the breast (d.i.c.), showing some pleomorphism in cell microanatomy at an ultrastructural level. We have obtained different sublines of 8701-BC cells by cloning in soft agar at different concentrations (0.3% and 0.6%), and we have characterized the cloned lines by some morphological and growth parameters. 8701-BC cells and clones have been submitted to analysis by reverse transcriptase-linked polymerase chain reaction to detect mRNAs of various cytokines (transforming growth factor-beta s, tumour necrosis factors, interleukin 1s, interleukin 6, parathyroid hormone-related peptide, gamma in…

Cancer Researchmedicine.medical_specialtyMolecular Sequence DataParathyroid hormoneBreast NeoplasmsPolymerase Chain ReactionTransforming Growth Factor betaInternal medicineGene expressionBiomarkers TumorTumor Cells CulturedmedicineHumansRNA MessengerMolecular BiologyBase SequencebiologyParathyroid hormone-related proteinInterleukin-6Tumor Necrosis Factor-alphaCarcinoma Ductal BreastParathyroid Hormone-Related ProteinProteinsInterleukinCell BiologyTransforming growth factor betaUrokinase-Type Plasminogen ActivatorMolecular biologyIn vitroClone CellsPhenotypeEndocrinologyCell culturebiology.proteinInterleukin-1Developmental BiologyTransforming growth factorDifferentiation
researchProduct

Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6.

1999

Signal transduction in response to interleukin-6 (IL-6) results from homodimerization of gp130. This dimerization occurs after binding of IL-6 to its surface receptor (IL-6R) and can also be triggered by the complex of soluble IL-6R and IL-6. We fused IL-6 to the constant region of a human IgG1 heavy chain (Fc). IL-6Fc was expressed in COS-7 cells and purified via Protein A Sepharose. Using three different assays we found that the biological activity of this dimeric IL-6 protein is comparable with monomeric IL-6. Recently, we described the designer cytokine Hyper-IL-6 (H-IL-6) in which soluble IL-6R and IL-6 are connected via a flexible peptide linker. This molecule turned out to be 100-100…

Carcinoma HepatocellularRecombinant Fusion ProteinsImmunologyBiologyProtein EngineeringMiceTumor Cells CulturedImmunology and AllergyAnimalsHumansReceptorCOS cellsInterleukin-6HydrolysisThrombinBiological activityProtein engineeringGlycoprotein 130Fusion proteinReceptors Interleukin-6In vitroImmunoglobulin Fc FragmentsBiochemistryImmunoglobulin GCOS CellsSignal transductionImmunoglobulin Heavy ChainsDimerizationJournal of immunological methods
researchProduct

A bioactive designer cytokine for human hematopoietic progenitor cell expansion

1997

Efficient expansion of hematopoietic progenitor cells requires, at least, the simultaneous stimulation of the receptors c-kit and gp130. While c-kit is activated by SCF; gp130, in cells which do not express sufficient amounts of IL-6R, can be activated by the complex of soluble IL-6R (sIL-6R) and IL-6. The therapeutic use of IL-6/sIL-6R, however, has been hampered by the high concentrations of the sIL-6R protein required. We have designed a fusion protein of sIL-6R and IL-6, linked by a flexible peptide chain, that was expressed to high levels. On gp130 expressing cells the fusion protein turned out to be fully active at 100 to 1,000-fold lower concentration than the combination of unlinked…

Carcinoma HepatocellularRecombinant Fusion Proteinsmedicine.medical_treatmentBiomedical EngineeringAntigens CD34BioengineeringBiologyApplied Microbiology and BiotechnologyProtein Structure SecondaryColony-Forming Units AssayAntigens CDTumor Cells CulturedmedicineHumansAmino Acid SequenceReceptorCells CulturedInterleukin 3Interleukin-6Cell growthLiver NeoplasmsReceptors InterleukinHematopoietic Stem CellsGlycoprotein 130Receptors Interleukin-6Fusion proteinCell biologyModels StructuralCytokineDrug DesignImmunologyCytokinesMolecular MedicineStem cellCell DivisionEx vivoBiotechnologyNature Biotechnology
researchProduct

Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy

2001

Although the etiopathogenesis of idiopathic dilated cardiomyopathy (IDC) is still unclear, it is widely accepted that a complex interplay between viral infections and immune mechanisms is the basis of disease genesis. Previously, we showed that heart-infiltrating T cells of patients suffering from acute, fulminant Coxsackie virus B3+-IDC shared a preferential usage of three variable gene segments of the T cell receptor beta chain-(TCR-Vbeta) encoding families Vbeta3, 7 and 13.1. This indicated the possible presence of a superantigen-driven immune response. Here, we further investigated the IDC immunological scenario by analysing different phenotypes of heart-infiltrating cells: TCR repertoi…

Cardiomyopathy DilatedInterleukin 2MyocarditisCD8 AntigensReceptors Antigen T-Cell alpha-betaT cellImmunologyCardiomyopathyGene Expressionchemical and pharmacologic phenomenaPicornaviridaeBiologyHLA-DQ alpha-ChainsImmunoenzyme TechniquesInterferon-gammaImmune systemAntigenHLA-DQ AntigensIdiopathic dilated cardiomyopathymedicineHLA-DQ beta-ChainsHumansImmunology and AllergyRNA MessengerAntigens ViralInterleukin-6Reverse Transcriptase Polymerase Chain ReactionHistocompatibility TestingMyocardiumIDC cytokines immune mechanismsmedicine.diseaseEnterovirus B HumanMyocarditismedicine.anatomical_structureCD4 AntigensImmunologyLeukocytes MononuclearCytokinesInterleukin-2Interleukin-4CD8Interleukin-1medicine.drug
researchProduct

Differential responses to docosahexaenoic acid in primary and immortalized cardiac cells

2013

Abstract The importance of dietary polyunsaturated fatty acids (PUFAs) in the reduction of cardiovascular disease has been recognized for many years. Docosahexaenoic acid (22:6n3, DHA) is an n-3 PUFA known to affect numerous biological functions and provide cardioprotection; however, the exact molecular and cellular protective mechanism(s) remain unknown. In contrast, DHA also possesses many anti-tumorgenic properties including suppressing cell growth and inducing apoptosis. In the present study, we investigated the effect of DHA toward H9c2 cells (an immortalized cardiac cell line) and neonatal primary cardiomyocytes (NCM). Cells were treated with 0 μM, 10 μM or 100 μM DHA for upto 48 h. C…

CardioprotectionDocosahexaenoic AcidsbiologyCaspase 3Cell SurvivalInterleukin-6Cell growthCytochrome cBlotting WesternCytochromes cGeneral MedicineMitochondrionToxicologyMitochondria HeartCell LineRatsCell biologyDocosahexaenoic acidApoptosiscardiovascular systembiology.proteinAnimalsMyocytes CardiacViability assayCaspaseToxicology Letters
researchProduct

1267 HSP70-2 polymorphism as a risk factor for carotid plaque rupture and cerebral ischaemia in old type 2 diabetes-atherosclerotic patients.

2005

Patients with type 2 diabetes mellitus (NIDDM) are at risk for macrovascular disease complications, such as myocardial infarction (MI) or stroke from plaque rupture. Cytokines play a key role in plaque vulnerability. IFN-gamma inhibits collagen synthesis thereby affecting plaque stability. High IL-6, TNF-alpha, and dyslipidemia are risk factors for thrombosis. Abnormal increments of HSP70 in atherosclerotic plaques might lead to plaque instability and rupture caused by chronic inflammation, which up-regulates the expression of pro-inflammatory cytokines (IL-6 and TNF-alpha) in human monocytes. Studies of a polymorphic PstI site lying in the coding region at position 1267 of the HSP70-2 gene…

Carotid Artery DiseasesMaleAgingmedicine.medical_specialtyGenotypeArteriosclerosisType 2 diabetesGastroenterologyBrain IschemiaInterferon-gammaGene FrequencyRisk FactorsInternal medicinemedicineHumansCarotid StenosisHSP70 Heat-Shock ProteinsMyocardial infarctionRNA MessengerAllelesTriglyceridesMacrovascular diseaseAgedGlycated HemoglobinRupturePolymorphism Geneticbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaType 2 Diabetes MellitusOdds ratioCholesterol LDLMiddle Agedmedicine.diseaseThrombosisEndocrinologyCarotid ArteriesDiabetes Mellitus Type 2Relative riskFemalebusinessDyslipidemiaDevelopmental BiologyMechanisms of ageing and development
researchProduct